BMS: biologics 75% of portfolio, will continue to invest in capabilities

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/shuvro ghose)
(Image: iStock/shuvro ghose)

Related tags: Bristol-myers squibb, Investment

Bristol-Myers Squibb has reported its third quarter revenues and an evolving operational model that includes a greater investment in R&D.

We just finished another very good quarter​,” Giovanni Caforio, Bristol-Myers Squibb CEO said during the company’s conference call yesterday.

The company closed the quarter with $4.9bn in revenue – a 21% increase over the same period last year, largely due in part to Opdivo. However, Caforio noted disappointing results from CheckMate -026, which he said will not change the company’s strategy moving forward.

We've applied learnings from the trial to our entire development program, and we are advancing a broad set of opportunities for Opdivo​,” he explained, adding that the company sees an “even more important role for combinations​.”

Over the next three to five years, Caforio said growth will be driven mainly by Eliquis, Opdivo, and Yervoy. Continuing to look forward, he explained the company will “evolve​” its operating model in four areas over the next 18 months in order to refocus on priorities.

We will prioritize resources to focus even more on a core set of key brands and a core set of key markets, positioned to drive growth over time​,” said Caforio.

This will include increasing R&D spend in 2017 versus 2016 – and specifically investing in biologics.

Biologics are now about 75% of our development portfolio, so we will continue to invest in our biologics capabilities, as evidenced by our recent investments in Devens and Cruiserath​,” explained Cofario.

As Biopharma-Reporter.com previously reported​, BMS recently invested $280m to complete an expansion of its Deven, MA-based biologics facility to support the company’s growing biologics portfolio.

We are committed to putting resources where we can deliver the greatest value​,” Charles A. Bancroft, Bristol-Myers Squibb CFO, added on the call. “We are evolving the company's operating model and believe these changes will help drive the company's continued success in the near and long term​.”

Related news

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Related suppliers

Follow us

Products

View more

Webinars